American Society of Hirudotherapy

DIEP flap in breast reconstruction: A morbidity study of bilateral versus unilateral reconstruction.

Research article published in Annales de chirurgie plastique et esthetique (2023)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsLaurent et al. · Annales de chirurgie plastique et esthetique, 2023

Abstract

BACKGROUND: The Deep Inferior Epigastric Perforator (DIEP) flap is a modality in breast reconstruction of choice. Despite its well-documented benefits and complications, a lack of evidence remains with regards to the risks of performing a bilateral versus a unilateral reconstruction. As such, we sought to compare the rates of adverse outcomes in the perioperative and postoperative periods associated with a unilateral versus a bilateral DIEP flap breast reconstruction. METHODS: A retrospective cohort study of 178 consecutive patients undergoing unilateral versus. bilateral deep inferior epigastric perforator flap breast reconstruction was performed at our tertiary care center over a 3-year period. Data on demographics, operative time, intraoperative and postoperative complications, and surgical re-exploration, were extracted for both groups. Statistical analysis was performed on a per-flap basis. RESULTS: A total of 157 unilateral and 42 bilateral deep inferior epigastric perforator flaps were identified. The rate of intra-operative complications was 12.1% for unilateral versus. 4.8% for bilateral flaps (P=0.26). Total post-operative complications rates were 30.6% for unilateral versus 54.7% for bilateral flaps (P=0.003). Surgical re-exploration was performed in 12.7% of unilateral and 11.9% of bilateral cases (P=0.88). The rate of total flap loss was similar between types of reconstruction, occurring in 2.5% of unilateral vs. 2.4% of bilateral flaps (P=1). CONCLUSION: This study demonstrates the rate of complications per flap is significantly higher in bilateral versus unilateral deep inferior epigastric perforator flap breast reconstruction. Bilateral DIEP breast reconstruction should be decided on a case-by-case basis. LEVEL OF EVIDENCE: Prognostic/Risk Study, Level II.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansMastectomyRetrospective StudiesPerforator FlapMammaplastyMorbidityPostoperative ComplicationsEpigastric Arteries

Summary

The Deep Inferior Epigastric Perforator (DIEP) flap is a modality in breast reconstruction of choice. Despite its well-documented benefits and complications, a lack of evidence remains with regards to the risks of performing a bilateral versus a unilateral reconstruction.

Why This Matters for Hirudotherapy

This retrospective cohort study compared perioperative and postoperative complication rates between unilateral and bilateral deep inferior epigastric perforator (DIEP) flap breast reconstructions, finding a significantly higher rate of complications per flap in bilateral procedures. The abstract outlines the risk profiles, surgical re-operation rates, and total flap loss rates associated with these complex microvascular procedures. However, the study focuses exclusively on surgical outcomes and does not detail specific salvage therapies or complications like venous congestion. The abstract contains no mention of leeches, hirudotherapy, or the leech secretome, resulting in no direct clinical relevance to the American Society of Hirudotherapy.

Citation

DIEP flap in breast reconstruction: A morbidity study of bilateral versus unilateral reconstruction.

Laurent et al. · Annales de chirurgie plastique et esthetique, 2023

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.